Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.35 |
| ▸ | MTOR | P42345 | 16/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24955763 | 1.00 | CNR2 (0.38) | CNR2NT5EPIK3CAMTORPIK3CG | |
| SCHEMBL31106958 | 0.83 | PDE2A (0.46) | PIK3CAMTOR | |
| SCHEMBL24955621 | 0.83 | PDE2A (0.46) | PIK3CAMTOR | |
| SCHEMBL31106981 | 0.81 | CNR2 (0.36) | CNR2PIK3CAMTORPIK3CGMAPK14 | |
| SCHEMBL24955674 | 0.81 | CNR2 (0.36) | CNR2PIK3CAMTORPIK3CGMAPK14 | |
| SCHEMBL24955764 | 0.81 | CNR2 (0.35) | CNR2PIK3CAMTOR | |
| SCHEMBL31106977 | 0.81 | CNR2 (0.35) | CNR2PIK3CAMTOR | |
| SCHEMBL24955626 | 0.80 | PIK3CA (0.42) | CNR2PIK3CAMTOR | |
| SCHEMBL24955619 | 0.80 | PIK3CA (0.42) | PIK3CAMTOR | |
| SCHEMBL31106961 | 0.80 | PIK3CA (0.42) | CNR2PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2024-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | SI, SLC10A2, NOS3 | CNR2 1522/4885NT5E 2980/4885PIK3CA 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.